PMID- 36335453
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221108
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 50
IP  - 6
DP  - 2022
TI  - Anethole ameliorates inflammation induced by monosodium urate in an acute gouty 
      arthritis model via inhibiting TLRs/MyD88 pathway.
PG  - 107-114
LID - 10.15586/aei.v50i6.682 [doi]
AB  - OBJECTIVE: To assess the effects of anethole on monosodium urate (MSU)-induced 
      inflammatory response, investigate its role in acute gouty arthritis (AGA), and 
      verify its molecular mechanism. METHODS: Hematoxylin and eosin staining assay and 
      time-dependent detection of degree of ankle swelling were performed to assess the 
      effects of anethole on joint injury in MSU-induced AGA mice. 
      Enzyme-linked-immunosorbent serologic assay was performed to demonstrate the 
      production levels of inflammatory factors (interleukin 1beta [IL-1beta], interleukin 6 
      [IL-6], interleukin 8 [IL-8], tumor necrosis factor alpha [TNF-alpha], and monocyte 
      chemo-attractant protein-1 [MCP-1]) in MSU-induced AGA mice. Western blot assays 
      were used to confirm the effects of anethole on oligomerization domain-like 
      receptor family pyrin domain-containing 3 (NLRP3) inflammasome activity and the 
      activation of toll-like receptors (TLRs)-myeloid differentiation factor 88 
      (MyD88) pathway in MSU-induced AGA mice. RESULTS: We observed that a significant 
      joint injury occurred in MSU-induced AGA mice. Anethole could alleviate the 
      pathological injury of the synovium in MSU-induced AGA mice and suppressed ankle 
      swelling. In addition, we observed that anethole could inhibit MSU-induced 
      inflammatory response and inflammasome activation in MSU-induced AGA mice. 
      Moreover, we discovered that anethole enabled to inhibit the activation of 
      TLRs/MyD88 pathway in MSU-induced AGA mice. Our findings further confirmed that 
      anethole contributed to the inhibitory effects on progression in MSU-induced AGA 
      mice. CONCLUSION: It confirmed that anethole ameliorated the MSU-induced 
      inflammatory response in AGA mice in vivo via inhibiting TLRs-MyD88 pathway.
FAU - Cao, Yuepeng
AU  - Cao Y
AD  - Department of Rheumatology and Immunology, Guizhou University of Traditional 
      Chinese Medicine, Guiyang, Guizhou Province, China.
FAU - Zhong, Qin
AU  - Zhong Q
AD  - Department of Rheumatology and Immunology, Guizhou University of Traditional 
      Chinese Medicine, Guiyang, Guizhou Province, China.
FAU - Tang, Fang
AU  - Tang F
AD  - Department of Rheumatology and Immunology, Guizhou University of Traditional 
      Chinese Medicine, Guiyang, Guizhou Province, China.
FAU - Yao, Xueming
AU  - Yao X
AD  - Department of Rheumatology and Immunology, Guizhou University of Traditional 
      Chinese Medicine, Guiyang, Guizhou Province, China.
FAU - Liu, Zhengqi
AU  - Liu Z
AD  - Department of Rheumatology and Immunology, Guizhou University of Traditional 
      Chinese Medicine, Guiyang, Guizhou Province, China; zq_liu81@163.com.
FAU - Zhang, Xiaodong
AU  - Zhang X
AD  - Second Clinical School of Medicine, Guizhou University of Traditional Chinese 
      Medicine, Guiyang, Guizhou Province, China.
LA  - eng
PT  - Journal Article
DEP - 20221101
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 268B43MJ25 (Uric Acid)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Inflammasomes)
RN  - Q3JEK5DO4K (anethole)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Myd88 protein, mouse)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Arthritis, Gouty/chemically induced/drug therapy
MH  - Uric Acid/adverse effects
MH  - Myeloid Differentiation Factor 88/metabolism
MH  - Inflammasomes/adverse effects/metabolism
MH  - Inflammation/pathology
MH  - Interleukin-1beta/adverse effects/metabolism
OTO - NOTNLM
OT  - TLRs/MyD88 pathway
OT  - acute gouty arthritis
OT  - anethole
OT  - inflammation
OT  - monosodium urate
COIS- The authors stated that there were no conflicts of interest to disclose.
EDAT- 2022/11/07 06:00
MHDA- 2022/11/09 06:00
CRDT- 2022/11/06 05:12
PHST- 2022/04/23 00:00 [received]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/11/06 05:12 [entrez]
PHST- 2022/11/07 06:00 [pubmed]
PHST- 2022/11/09 06:00 [medline]
AID - 10.15586/aei.v50i6.682 [doi]
PST - epublish
SO  - Allergol Immunopathol (Madr). 2022 Nov 1;50(6):107-114. doi: 
      10.15586/aei.v50i6.682. eCollection 2022.